| First Author | Caillaud M | Year | 2019 |
| Journal | PLoS One | Volume | 14 |
| Issue | 2 | Pages | e0212663 |
| PubMed ID | 30785960 | Mgi Jnum | J:273361 |
| Mgi Id | MGI:6281248 | Doi | 10.1371/journal.pone.0212663 |
| Citation | Caillaud M, et al. (2019) Trans epsilon viniferin decreases amyloid deposits and inflammation in a mouse transgenic Alzheimer model. PLoS One 14(2):e0212663 |
| abstractText | As Alzheimer's disease (AD) induces several cellular and molecular damages, it could be interesting to use multi-target molecules for therapeutics. We previously published that trans epsilon-viniferin induced the disaggregation of Abeta42 peptide and inhibited the inflammatory response in primary cellular model of AD. Here, effects of this stilbenoid were evaluated in transgenic APPswePS1dE9 mice. We report that trans epsilon-viniferin could go through the blood brain barrier, reduces size and density of amyloid deposits and decreases reactivity of astrocytes and microglia, after a weekly intraperitoneal injection at 10 mg/kg from 3 to 6 months of age. |
